Norethindrone

Norethindrone is a lipid of Sterol Lipids (ST) class. Norethindrone is associated with abnormalities such as Endometriosis, site unspecified, Wiskott-Aldrich Syndrome and Estrogenic effect. The involved functions are known as Hemorrhage, Phosphorylation, Apoptosis, DNA Repair and Cell Cycle. Norethindrone often locates in Blood, Back, Body tissue, Nucleolar and Human tissue. The associated genes with Norethindrone are MMP gene, NR3C1 gene and Genes, Reporter. The related lipids are Steroids, 4,17 beta-dihydroxy-4-androstene-3-one, 4-estren-3,17-diol and Estranes.

Cross Reference

Introduction

To understand associated biological information of Norethindrone, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Norethindrone?

Norethindrone is suspected in Endometriosis, site unspecified, Estrogenic effect and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Norethindrone

MeSH term MeSH ID Detail
Pancreatic Neoplasms D010190 77 associated lipids
Body Weight D001835 333 associated lipids
Arteriosclerosis D001161 86 associated lipids
Total 3

PubChem Associated disorders and diseases

What pathways are associated with Norethindrone

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Norethindrone?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Norethindrone?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Norethindrone?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Norethindrone?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Norethindrone?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Norethindrone

Download all related citations
Per page 10 20 50 100 | Total 3869
Authors Title Published Journal PubMed Link
Oosterbaan HP et al. The effects of continuous combined transdermal oestrogen-progestogen treatment on bleeding patterns and the endometrium in postmenopausal women. 1995 Maturitas pmid:7616870
Cagnacci A et al. A comparison of the central effects of different progestins used in hormone replacement therapy. 2004 Maturitas pmid:15283939
Lazar F et al. Carotid and uterine vascular resistance in short-term hormone replacement therapy postmenopausal users. 2004 Maturitas pmid:15283941
Norman-Taylor JQ et al. Hormone replacement therapy by the transdermal administration of oestradiol and norethisterone. 1994 Maturitas pmid:8015505
Kurtay G et al. A comparison of effects of sequential transdermal administration versus oral administration of estradiol plus norethisterone acetate on serum NO levels in postmenopausal women. 2006 Maturitas pmid:16325022
Klehr-Bathmann I and Kuhl H Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate. 1995 Maturitas pmid:7616874
Kaiser R Duration of the climacteric syndrome in women treated by hormonal substitution and in controls. 1984 Maturitas pmid:6727694
Campagnoli C et al. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report. 1994 Maturitas pmid:7935029
Nordin BE et al. A placebo-controlled trial of ethinyl oestradiol and norethisterone in climacteric women. 1980 Maturitas pmid:7003315
Lundström E et al. Digitized assessment of mammographic breast density--effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo. 2011 Maturitas pmid:21958943
Perry W and Wiseman RA Combined oral estradiol valerate-norethisterone treatment over 3 years in postmenopausal women: effect on lipids, coagulation factors, haematology and biochemistry. 2002 Maturitas pmid:12065175
Pedersen NG et al. Progestins used in hormonal replacement therapy display different effects in coronary arteries from New Zealand white rabbits. 2004 Maturitas pmid:15531126
Piccioni P et al. Hormonal replacement therapy after stem cell transplantation. 2004 Maturitas pmid:15531129
Samsioe G et al. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. 2007 Maturitas pmid:17317046
Franke HR and Vermes I Differential effects of progestogens on breast cancer cell lines. 2003 Maturitas pmid:14670646
Christodoulacos G et al. Transvaginal sonographic monitoring of the uterine effects of raloxifene and a continuous combined replacement therapy in postmenopausal women. 2002 Maturitas pmid:12020983
Norris LA et al. Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy. 2002 Maturitas pmid:12385861
Brynhildsen J and Hammar M Lipids and clotting factors during low dose transdermal estradiol/norethisterone use. 2005 Maturitas pmid:15780536
Volpe A et al. Benefits and risks of different hormonal replacement therapies in post-menopausal women. 1986 Maturitas pmid:3033444
Bjarnason K et al. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. 1999 Maturitas pmid:10515673
Seeger H et al. In vitro effects of tibolone and its metabolites on human vascular coronary cells. 2007 Maturitas pmid:17572028
Fink BJ Endometrial changes after long-term use of continuous oestrogen and cyclic progestogen. 1984 Maturitas pmid:6738374
Bruhat M et al. Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study. 2001 Maturitas pmid:11731187
Eilertsen AL et al. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. 2005 Maturitas pmid:16186073
Sporrong T et al. A novel statistical approach to analysis of bleeding patterns during continuous hormone replacement therapy. 1989 Maturitas pmid:2593864
Yilmazer M et al. Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. 2003 Maturitas pmid:14625121
Cengiz B et al. Effect of hormone replacement therapy on serum levels of tumor markers in healthy postmenopausal women. 2003 Maturitas pmid:14625127
Nerbrand C et al. Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides. 2002 Maturitas pmid:12020980
Ruan X et al. The pharmacology of dienogest. 2012 Maturitas pmid:22364708
Polisseni AF et al. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study. 2013 Maturitas pmid:23201326
Christiansen C et al. Low-risk lipoprotein pattern in post-menopausal women on sequential oestrogen/progestogen treatment. 1984 Maturitas pmid:6727693
Christodoulakos G et al. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene. 2005 Maturitas pmid:15780533
Riis BJ et al. Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women. 1988 Maturitas pmid:3041248
Grasso A et al. Endocrinological features and endometrial morphology in climacteric women receiving hormone replacement therapy. 1982 Maturitas pmid:6285153
Dahmoun M et al. Apoptosis, proliferation, and sex steroid receptors in postmenopausal endometrium before and during HRT. 2004 Maturitas pmid:15474755
Christodoulakos GE et al. The effect of low dose hormone therapy on mammographic breast density. 2006 Maturitas pmid:16198519
von Holst T et al. Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone. 2002 Maturitas pmid:12468135
Fernandes CE et al. Effects of estradiol and norethisterone on lipids, insulin resistance and carotid flow. 2008 Maturitas pmid:18359175
Thunell L et al. The effect of continuous combined HRT on glucose homeostasis and plasma lipids. A placebo-controlled study in postmenopausal women with type 2 diabetes. 2006 Maturitas pmid:16198072
Luotola H et al. Effects of natural oestrogen/progestogen substitution therapy on carbohydrate and lipid metabolism in post-menopausal women. 1986 Maturitas pmid:3537636
Zhou J et al. Medroxyprogesterone acetate-driven increase in breast cancer risk might be mediated via cross-talk with growth factors in the presence of progesterone receptor membrane component-1. 2013 Maturitas pmid:23856385
Riis BJ and Christiansen C Post-menopausal bone loss: effects of oestrogens and progestogens. A review. 1986 Maturitas pmid:3553863
al-Azzawi F et al. Investigation of the bleeding patterns of postmenopausal women treated with Estrapak-50. 1994 Maturitas pmid:8177092
Posaci C et al. Effects of HRT on serum levels of IGF-I in postmenopausal women. 2001 Maturitas pmid:11684375
Lübbert H and Nauert C Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern. 1997 Maturitas pmid:9522319
Gambacciani M et al. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. 2003 Maturitas pmid:12590012
Glusa E et al. Mechanisms of relaxation of rat aorta in response to progesterone and synthetic progestins. 1997 Maturitas pmid:9522326
Peverill RE et al. Comparison of effects of pravastatin and hormone therapy on soluble P-selectin and platelet P-selectin expression in postmenopausal hypercholesterolemic women. 2006 Maturitas pmid:16368469
Popp AW et al. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy. 2006 Maturitas pmid:16368472
Stadberg E et al. 17 beta-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy. 1996 Maturitas pmid:8861084
Raudaskoski TH et al. Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device. 1995 Maturitas pmid:7666816
Lindgren R et al. Transdermal hormonal replacement therapy with transdermal progestin every second month. 1995 Maturitas pmid:7666813
Byrjalsen I et al. Serum placental protein 14 in pre-menopausal and post-menopausal women--dependency on oestrogen/progestogen status. 1990 Maturitas pmid:2255265
Saarikoski S et al. Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders. 1990 Maturitas pmid:2255266
Dören M and Schneider HP Long-term compliance of continuous combined estrogen and progestogen replacement in postmenopausal women. 1996 Maturitas pmid:8905600
Mattsson LA et al. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. 1982 Maturitas pmid:7121296
Schindler AE et al. Classification and pharmacology of progestins. 2003 Maturitas pmid:14670641
Jensen J et al. Long-term and withdrawal effects of two different oestrogen-progestogen combinations on lipid and lipoprotein profiles in post-menopausal women. 1989 Maturitas pmid:2547137
Need AG et al. Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis. 1986 Maturitas pmid:3574140
Campagnoli C et al. Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. 2002 Maturitas pmid:12034517
Obel EB et al. A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment. 1993 Maturitas pmid:8429800
Hellberg D and Nilsson S Comparison of a triphasic oestradiol/norethisterone acetate preparation with and without an oestriol component in the treatment of climacteric complaints. 1984 Maturitas pmid:6429481
Keller PJ et al. A transdermal regimen for continuous combined hormone replacement therapy in the menopause. 1992 Maturitas pmid:1465033
Mehring W [The effect of ovulation inhibitors on the vaginal picture and the portio epithelium]. 1965 Med Klin pmid:5870226
Norethindrone--the "minipill". 1973 Med Lett Drugs Ther pmid:4712978
Norinyl 1+80 and Ortho-Novum 1/80. 1969 Med Lett Drugs Ther pmid:5778361
Ortho-Novum 10/11--a new "bi-phasic" oral contraceptive. 1982 Med Lett Drugs Ther pmid:7121396
Three new combination oral contraceptives: Seasonique, Loestrin 24 Fe, and Yaz. 2006 Med Lett Drugs Ther pmid:17001297
Lachnit-Fixson U and Aydinlik S [New cycle-stabilizing contraceptive agent (Ediwal)]. 1976 Med Monatsschr pmid:979900
Zaffaroni A Systems for controlled drug delivery. 1981 Med Res Rev pmid:7050567
GOLDFARB AF et al. OVULATION CONTROL. 1963 Med Sci pmid:14081010
DEHAEN P THERAPEUTIC RESEARCH IN REVIEW. 1964 Med Sci pmid:14143127
Ranneberg KM and Holzmann H [Herpes gestationis recurrence caused by synthetic gestagens]. 1970 Med Welt pmid:4249079
HEINEN G [Oral contraception]. 1962 Med Welt pmid:13953432
GOLDZIEHER JW NEWER DRUGS IN ORAL CONTRACEPTION. 1964 Med. Clin. North Am. pmid:14149247
Stoll BA Therapy by progestational agents in advanced breast cancer. 1966 Med. J. Aust. pmid:5906684
CUNINGHAM K and LANG WR Result of a blind clinical trial conducted on 50 cases of hormonal mastopathy. 1962 Med. J. Aust. pmid:14024258
Roxburgh DR and West MJ The use of norethisterone to suppress menstruation in the intellectually severely retarded woman. 1973 Med. J. Aust. pmid:4746398
Kneale B and Evans J Progestogen therapy for advanced carcinoma of the endometrium. 1969 Med. J. Aust. pmid:5374044
Fraser IS and Weisberg E A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. 1981 Med. J. Aust. pmid:6453269
MacLennan AH et al. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. 1993 Med. J. Aust. pmid:8336583
PLANT GH PRODUCTION AND QUALITY CONTROL OF AN ORAL CONTRACEPTIVE. 1965 Med. J. Aust. pmid:14265218
BROWN MM PREMENSTRUAL METATARSALGIA. 1965 Med. J. Aust. pmid:14315259
Wren BG Minimal dose combined hormonal replacement therapy for menopausal women. 1981 Med. J. Aust. pmid:7242418
Gattanell PN et al. Hepatocellular carcinoma in a young woman with prolonged exposure to oral contraceptives. 1978 Med. Pediatr. Oncol. pmid:207962
Czarnecka D et al. The effect of hormone replacement therapy on endothelial function in postmenopausal women with hypertension. 2004 Med. Sci. Monit. pmid:14737044
Kyriakou A and Skordis N Thalassaemia and aberrations of growth and puberty. 2009 Mediterr J Hematol Infect Dis pmid:21415985
Georgiev DB and Manassiev NA Effect of long-term continuous combined hormone replacement therapy with estradiol valerate and either dienogest or norethisterone acetate on mammographic density in postmenopausal women. 2002 Jul-Aug Medscape Womens Health pmid:12466733
Krämer EA et al. The effects of progesterone, medroxyprogesterone acetate, and norethisterone on growth factor- and estradiol-treated human cancerous and noncancerous breast cells. 2005 Jul-Aug Menopause pmid:16037763
Speroff L et al. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms. 2000 Nov-Dec Menopause pmid:11127760
Brynhildsen J and Hammar M Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women. 2002 Mar-Apr Menopause pmid:11875333
Christodoulakos GE et al. The effect of hormone therapy and raloxifene on serum matrix metalloproteinase-2 and -9 in postmenopausal women. 2004 May-Jun Menopause pmid:15167309
Dören M et al. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. 1999 Menopause pmid:10614676
Samsioe G et al. Changes in lipid and lipoprotein profile in postmenopausal women receiving low-dose combinations of 17beta-estradiol and norethisterone acetate. 2002 Sep-Oct Menopause pmid:12218722
Mueck AO et al. Medroxyprogesterone acetate versus norethisterone: effect on estradiol-induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures. 2002 Jul-Aug Menopause pmid:12082363
Seeger H et al. Effect of medroxyprogesterone acetate and norethisterone on serum-stimulated and estradiol-inhibited proliferation of human coronary artery smooth muscle cells. 2001 Jan-Feb Menopause pmid:11201515
Ursic-Vrscaj M et al. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. 2001 Jan-Feb Menopause pmid:11201519
Botteman MF et al. A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms. 2004 May-Jun Menopause pmid:15167315
Vitale C et al. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. 2005 Sep-Oct Menopause pmid:16145309
Rinaldi M et al. Neutral effect of prolonged transdermal hormone therapy on liver function of postmenopausal women with chronic active hepatitis. 2005 Sep-Oct Menopause pmid:16145317